UA112425C2 - ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ - Google Patents

ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ

Info

Publication number
UA112425C2
UA112425C2 UAA201308896A UAA201308896A UA112425C2 UA 112425 C2 UA112425 C2 UA 112425C2 UA A201308896 A UAA201308896 A UA A201308896A UA A201308896 A UAA201308896 A UA A201308896A UA 112425 C2 UA112425 C2 UA 112425C2
Authority
UA
Ukraine
Prior art keywords
inhibitors
tyrosininas
typininase
indasol
imidaso
Prior art date
Application number
UAA201308896A
Other languages
English (en)
Inventor
Марк Лоуренс БОЙЗ
Роберт Кірк Делісл
Ерік Джеймс Хікен
Ейпріл Л. Кенеді
Девід А. Мареска
Фредрік П. Мармсетер
Марк К. МАНСОН
Бред Ньюхаус
Брайсон РАСТ
Джеймс П. Ріці
Марта Е. Родріґес
Джордж Т. ТОПАЛОВ
Цзянь ЧЖАО
Original Assignee
Еррей Біофарма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еррей Біофарма Інк. filed Critical Еррей Біофарма Інк.
Publication of UA112425C2 publication Critical patent/UA112425C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Сполуки Формули І та їх фармацевтично прийнятні солі, в яких R, R, R, R, Rй Rмають значення, зазначені в описі, є інгібіторами cFMS і корисні в лікуванні фіброзу, кісткових захворювань, раку, аутоімунних порушень, запальних захворювань, серцево-судинних захворювань, болю й опіків у ссавця.I
UAA201308896A 2010-12-13 2011-12-13 ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ UA112425C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42254710P 2010-12-13 2010-12-13
PCT/US2011/064549 WO2012082689A1 (en) 2010-12-13 2011-12-13 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
UA112425C2 true UA112425C2 (uk) 2016-09-12

Family

ID=45478484

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201308896A UA112425C2 (uk) 2010-12-13 2011-12-13 ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ

Country Status (32)

Country Link
US (3) US9174981B2 (uk)
EP (1) EP2651939B1 (uk)
JP (3) JP5868996B2 (uk)
KR (1) KR101974665B1 (uk)
CN (3) CN105924437B (uk)
AU (3) AU2011344001B2 (uk)
BR (1) BR112013014854B1 (uk)
CA (2) CA2821712C (uk)
CL (1) CL2013001712A1 (uk)
CO (1) CO6751248A2 (uk)
CR (1) CR20130349A (uk)
DK (1) DK2651939T3 (uk)
ES (1) ES2540996T3 (uk)
HK (1) HK1190709A1 (uk)
HR (1) HRP20150571T1 (uk)
HU (1) HUE025416T2 (uk)
IL (1) IL226911A (uk)
ME (1) ME02172B (uk)
MX (1) MX2013006763A (uk)
MY (1) MY172110A (uk)
NZ (1) NZ613235A (uk)
PL (1) PL2651939T3 (uk)
PT (1) PT2651939E (uk)
RS (1) RS54070B1 (uk)
RU (1) RU2591195C2 (uk)
SG (1) SG191129A1 (uk)
SI (1) SI2651939T1 (uk)
SM (1) SMT201500165B (uk)
TW (1) TWI527813B (uk)
UA (1) UA112425C2 (uk)
UY (1) UY33801A (uk)
WO (1) WO2012082689A1 (uk)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2516433T3 (pl) * 2009-12-21 2014-10-31 Array Biopharma Inc Podstawione związki N-(1H-indazol-4-ilo)imidazo[1,2-a]pirydyno-3-karboksyamidowe jako inhibitory cFMS
WO2012082689A1 (en) * 2010-12-13 2012-06-21 Array Biopharma Inc. SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CN104974078A (zh) * 2015-06-25 2015-10-14 黄荣辉 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
MX2018001751A (es) 2015-08-11 2018-08-01 Neomed Inst Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos.
WO2017024412A1 (en) 2015-08-12 2017-02-16 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
WO2017077280A1 (en) * 2015-11-02 2017-05-11 Sonia Lain Tetrahydroindazoles and medical uses thereof
CN105198799A (zh) * 2015-11-03 2015-12-30 江苏梦得电镀化学品有限公司 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
MX2018015625A (es) 2016-06-14 2019-03-06 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
WO2018019291A1 (en) * 2016-07-29 2018-02-01 The Hong Kong University Of Science And Technology C(sp3)-c(sp2) cross-coupling reaction of organozinc reagents and heterocyclic (pseudo)halides
AU2017355603A1 (en) 2016-11-04 2019-06-20 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
CA3041986A1 (en) * 2016-11-28 2018-05-31 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
FI3658552T3 (fi) 2017-07-28 2023-11-16 Yuhan Corp Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
MX2021008931A (es) 2019-01-24 2021-08-24 Daiichi Sankyo Co Ltd Compuesto de urea que tiene sustituyentes.
JP2022548696A (ja) 2019-09-18 2022-11-21 武田薬品工業株式会社 血漿カリクレインインヒビター及びその使用
JP2022549601A (ja) 2019-09-18 2022-11-28 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7259179B2 (en) 2002-05-23 2007-08-21 Cytopia Research Pty Ltd Kinase inhibitors
WO2008078100A2 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
JP5374492B2 (ja) * 2007-04-03 2013-12-25 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害薬としてのイミダゾ［１，２−ａ］ピリジン化合物
FR2925901B1 (fr) 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EP2280705B1 (en) 2008-06-05 2014-10-08 Glaxo Group Limited Novel compounds
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
PL2516433T3 (pl) 2009-12-21 2014-10-31 Array Biopharma Inc Podstawione związki N-(1H-indazol-4-ilo)imidazo[1,2-a]pirydyno-3-karboksyamidowe jako inhibitory cFMS
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2012082689A1 (en) 2010-12-13 2012-06-21 Array Biopharma Inc. SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用

Also Published As

Publication number Publication date
RU2013132758A (ru) 2015-01-20
TWI527813B (zh) 2016-04-01
ES2540996T3 (es) 2015-07-15
EP2651939B1 (en) 2015-04-08
AU2018201903A1 (en) 2018-04-12
CN103347882B (zh) 2016-05-11
CN109608449A (zh) 2019-04-12
HK1190709A1 (en) 2014-07-11
MY172110A (en) 2019-11-14
AU2018201903B2 (en) 2019-09-19
US20130274244A1 (en) 2013-10-17
JP2016040303A (ja) 2016-03-24
CR20130349A (es) 2013-08-09
US9174981B2 (en) 2015-11-03
BR112013014854A2 (pt) 2016-10-18
CN105924437B (zh) 2018-11-30
PT2651939E (pt) 2015-08-04
RS54070B1 (en) 2015-10-30
SMT201500165B (it) 2015-09-07
SI2651939T1 (sl) 2015-07-31
US10669269B2 (en) 2020-06-02
DK2651939T3 (en) 2015-06-01
JP5868996B2 (ja) 2016-02-24
RU2591195C2 (ru) 2016-07-10
JP2013545808A (ja) 2013-12-26
CA3027814A1 (en) 2012-06-21
AU2011344001B2 (en) 2016-06-30
US20180086758A1 (en) 2018-03-29
ME02172B (me) 2015-10-20
UY33801A (es) 2013-06-28
MX2013006763A (es) 2014-01-08
KR101974665B1 (ko) 2019-05-02
US9809590B2 (en) 2017-11-07
BR112013014854B1 (pt) 2020-12-08
KR20140014109A (ko) 2014-02-05
CA2821712C (en) 2019-02-12
BR112013014854A8 (pt) 2018-03-27
CA2821712A1 (en) 2012-06-21
JP2018065835A (ja) 2018-04-26
CO6751248A2 (es) 2013-09-16
CN103347882A (zh) 2013-10-09
AU2016222468A1 (en) 2016-09-22
EP2651939A1 (en) 2013-10-23
TW201305156A (zh) 2013-02-01
HUE025416T2 (en) 2016-02-29
IL226911A (en) 2016-09-29
AU2016222468B2 (en) 2017-12-21
CN105924437A (zh) 2016-09-07
WO2012082689A1 (en) 2012-06-21
SG191129A1 (en) 2013-07-31
US20160002232A1 (en) 2016-01-07
PL2651939T3 (pl) 2015-10-30
CL2013001712A1 (es) 2013-12-06
HRP20150571T1 (en) 2015-07-03
NZ613235A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
UA112425C2 (uk) ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
UA108222C2 (xx) СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS
CY1120154T1 (el) Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1
NI201200072A (es) Métodos y composiciones para tratar cáncer
IN2014DN09352A (uk)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
IN2014DN09348A (uk)
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201492082A1 (ru) Кристаллические формы ингибитора тирозинкиназы брутона
MX2015017964A (es) Inhibidores de bromodominio.
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
MA33939B1 (fr) 5-alcynyl-pyrimidines
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
WO2011150201A3 (en) Azolyl amide compounds and methods of use thereof
IN2014DN09347A (uk)
IN2013DN02555A (uk)
IN2012DN06061A (uk)
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
CY1116345T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ Ν-(1Η-ΙΝΔΑΖΟΛ-4-ΥΛ)ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΟ-3-ΚΑΡΒΟΞΑΜΙΔΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ ΥΠΟΔΟΧΕΑ ΤΥΠΟΥ III
EA201390619A1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
CY1115468T1 (el) Ενωσεις υποκατεστημενου ν-(1η-ινδαζολ-4υλ)ιμιδαζο[1,2-α]πυριδινο-3-καρβοηαμιδιου ως αναστολεις cfms